1. Investigations Using Albumin Binders to Modify the Tissue Distribution Profile of Radiopharmaceuticals Exemplified with Folate Radioconjugates.
- Author
-
Busslinger, Sarah D., Becker, Anna E., Vaccarin, Christian, Deberle, Luisa M., Renz, Marie-Luise, Groehn, Viola, Schibli, Roger, and Müller, Cristina
- Subjects
ALBUMINS ,IN vitro studies ,KIDNEYS ,IN vivo studies ,ANIMAL experimentation ,TIME ,RADIOISOTOPES ,RATS ,COMPARATIVE studies ,CHEMICAL elements ,RADIOPHARMACEUTICALS ,RESEARCH funding ,BLOOD circulation ,DESCRIPTIVE statistics ,OXIDOREDUCTASES ,BENZOATES ,FOLIC acid ,CELL lines ,MOLECULAR structure ,SHORT-chain fatty acids ,RADIATION dosimetry - Abstract
Simple Summary: Delivering high radiation dose to a tumor is a crucial prerequisite for therapeutic radiopharmaceuticals. It was previously shown that folate radioconjugates profit from modification with an albumin-binding moiety, which results in increased tumor uptake and reduced retention in the kidneys. In this study, the impact of the type of albumin binder and adjacent linker entity was systematically investigated. It was revealed that 4-(p-iodophenyl)butanoate binds to albumin with higher affinity than 5-(p-iodophenyl)pentanoate, and the presence of an adjacent hydrophobic 4-(aminomethyl)benzoic acid (AMBA) linker increased the binding in both cases even further. Stronger albumin-binding properties translated into enhanced blood residence of the respective folate radioconjugates, while the blood circulation time was found to be inversely linked to the radioconjugates' renal accumulation. This study demonstrated that subtle changes in the albumin-binding entity and the adjacent linker unit can serve for fine-tuning the radioconjugates' tissue distribution profiles to find an optimum tumor uptake and a balance between retention in the blood and kidneys. Introducing an albumin-binding entity into otherwise short-lived radiopharmaceuticals can be an effective means to improve their pharmacokinetic properties due to enhanced blood residence time. In the current study, DOTA-derivatized albumin binders based on 4-(p-iodophenyl)butanoate (DOTA-ALB-1 and DOTA-ALB-3) and 5-(p-iodophenyl)pentanoate entities (DOTA-ALB-24 and DOTA-ALB-25) without and with a hydrophobic 4-(aminomethyl)benzoic acid (AMBA) linker unit, respectively, were synthesized and labeled with lutetium-177 for in vitro and in vivo comparison. Overall, [
177 Lu]Lu-DOTA-ALB-1 demonstrated ~3-fold stronger in vitro albumin-binding affinity and a longer blood residence time (T50%IA ~8 h) than [177 Lu]Lu-DOTA-ALB-24 (T50%IA ~0.8 h). Introducing an AMBA linker enhanced the albumin-binding affinity, resulting in a T50%IA of ~24 h for [177 Lu]Lu-DOTA-ALB-3 and ~2 h for [177 Lu]Lu-DOTA-ALB-25. The same albumin binders without or with the AMBA linker were incorporated into 6R- and 6S-5-methyltetrahydrofolate-based DOTA-conjugates (177 Lu-RedFols). Biodistribution studies in mice performed with both diastereoisomers of [177 Lu]Lu-RedFol-1 and [177 Lu]Lu-RedFol-3, which comprised the 4-(p-iodophenyl)butanoate moiety, demonstrated a slower accumulation in KB tumors than those of [177 Lu]Lu-RedFol-24 and [177 Lu]Lu-RedFol-25 with the 5-(p-iodophenyl)pentanoate entity. In all cases, the tumor uptake was high (30–45% IA/g) 24 h after injection. Both diastereoisomers of [177 Lu]Lu-RedFol-1 and [177 Lu]Lu-RedFol-3 demonstrated high blood retention (3.8–8.7% IA/g, 24 h p.i.) and a 2- to 4-fold lower kidney uptake than the corresponding diastereoisomers of [177 Lu]Lu-RedFol-24 and [177 Lu]Lu-RedFol-25, which were more rapidly cleared from the blood (<0.2% IA/g, 24 h after injection). Kidney retention of the 6S-diastereoisomers of all177 Lu-RedFols was consistently higher than that of the respective 6R-diastereoisomers, irrespective of the albumin binder and linker unit used. It was demonstrated that the blood clearance data obtained with177 Lu-DOTA-ALBs had predictive value for the blood retention times of the respective folate radioconjugates. The use of these albumin-binding entities without or with an AMBA linker may serve for fine-tuning the blood retention of folate radioconjugates and also other radiopharmaceuticals and, hence, optimize their tissue distribution profiles. Dosimetry estimations based on patient data obtained with one of the most promising folate radioconjugates will be crucial to identify the dose-limiting organ, which will allow for selecting the most suitable folate radioconjugate for therapeutic purposes. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF